Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) in Q1 CY2025, with sales flat year on year at $6.67 billion. The ...

As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are ...

Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle claims it used speaker ...

Over the years, a host of large drugmakers have inked settlements with the federal authorities to resolve allegations that ...

Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit accusing the drugmaker of civil fraud for paying ...

The company paid to settle allegations of paying kickbacks to doctors in exchange for prescribing several of its HIV ...

In the hunt for a remedy, when the baton is passed from dedicated academic scientists to an innovative company to trusted community advocates, outcomes for society can be especially powerful.

After counsel withdrew for some of the plaintiffs in a huge consolidated legal battle between Gilead Sciences and patients ...

Gilead Sciences agreed to pay $202 million to the ... Gilead's expensive antiretroviral medications to patients with HIV, prosecutors announced Tuesday. Gilead gave the money to doctors who ...

Gilead Sciences to Pay $202 Million in US Settlement Over HIV Drug Kickbacks By Jonathan Stempel NEW YORK (Reuters) -Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit ...

Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan ...